Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Comparative tumour localization properties of radiolabelled monoclonal antibody preparations of defined immunoreactivities

  • 19 Accesses

  • 5 Citations

Abstract

The immunoreactive fraction of an anti-CEA monoclonal antibody preparation has been progressively decreased by the addition of increasing proportions of impurity in the form of immunologically inert mouse immunoglobulin. Following radioiodination, the immunoreactive fractions of the preparations were determined and their localization in a human tumour xenograft in nude mice was assessed. There was a progressive decline in tumour localization, from tumour to blood ratios of 2:1 with unadulterated antibody to 0.6:1 with preparations only 15% with respect to the initial antibody. These findings demonstrate that the immunoreactive fraction of monoclonal antibody preparations is a major limiting factor in tumour localization and this has implications for experimental and clinical applications of monoclonal antibodies.

This is a preview of subscription content, log in to check access.

References

  1. Beaumier P, Neuzil D, Yang HM, Noll EA, Kishore R, Eary JF, Krohn KA, Nelp WB, Hellstrom KE, Hellstrom I (1986) Immunoreactivity assay for labelled anti-melanoma monoclonal antibodies. J Nucl Med 27:824–828

  2. Douillard J-Y, Chatal J-F, Saccavini J-L, Curtet C, Kremer M, Peuvres P, Koprowski H (1985) Pharmacokinetic study of radiolabeled anti-colorectal carcinoma monoclonal antibodies in tumor-bearing mice. Eur J Nucl Med 11:107–113

  3. Ey PL, Prowse SJ, Jenkins CR (1978) The isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein-A sepharose. Immunochemistry 15:429–436

  4. Fraker PJ, Speck JC (1978) Protein and cell membrane iodination with a sparingly soluble chlorimade 1, 3, 4, 6, tetrachloro-3α, 6α-diphenyl-glycoluril. Biochem Biophys Res Commun 80:849–857

  5. Hagan PL, Halpern SE, Chen A, Krishnan L, Frincke J, Bartholomew RM, David GS, Carlo D (1985) In vivo kinetics of radiolabeled monoclonal anti-CEA antibodies in animal models. J Nucl Med 26:1418–1423

  6. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA (1984) Determination of the immunoreactive fraction of radiolabelled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77–89

  7. Matzku S, Kirchgessner H, Dippold WG, Bruggen J (1985) Immunoreactivity of monoclonal anti-melanoma antibodies in relation to the amount of radioactive iodine substituted to the antibody molecule. Eur J Nucl Med 11:260–264

  8. Motoyama T, Watanabe M (1983) Carcinoembryonic antigen production in human gastric cancer cell lines in vitro and in nude mice. Gann 74:679–686

  9. Murray JL, Rosenblum MG, Sobol RE, Bartholomew RM, Plager LE, Haynie TP, Jahns MF, Glenn HJ, Lamki L, Benjamin RS, Papadopoulos N, Boddie AW, Frinke JM, David GS, Carlo DJ, Hersh E (1985) Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5. Cancer Res 45:2376–2381

  10. Partridge CS, Britton DW, Bagshawe KD (1985) Use of the direct linear plot to estimate, in an immunoglobulin solution, the proportion which is specific monoclonal antibody against an unknown cell surface antigen. J Immunol Methods 78:95–101

  11. Perkins AC, Pimm MV, Birch MK (1985) The preparation and characterization of 111In-labelled 791T/36 monoclonal antibody for tumour immunoscintigraphy. Eur J Nucl Med 10:296–301

  12. Pimm MV, Baldwin RW (1985) The influence of increasing specific activity on the immunological reactivity of 131I-labelled antitumour monoclonal antibody. IRCS Med Sci 13:497–498

  13. Pimm MV, Embleton MJ, Perkins AC, Price MR, Robins RA, Robinson GR, Baldwin RW (1982) In vivo localization of antiosteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts. Int J Cancer 30:75–85

  14. Pimm MV, Pascoe W, Robins RA, Price MR, Baldwin RW (1986) Effect of protein mass on the pharmacokinetics and tumour discrimination of a murine monoclonal antibody in a rat mammary tumour model. IRCS Med Sci 14:876–877

  15. Pimm MV, Perkins AC, Baldwin RW (1987) Diverse characteristics of 111In labelled anti-CEA monoclonal antibodies for tumour immunoscintigraphy: radiolabelling, biodistribution and imaging studies in mice with human tumour xenografts. Eur J Nucl Med 12:515–521

  16. Reynolds J, Fejka R, Rothman M, Farkas R, Larson S (1985) Loss of immunoreactivity of I-131 labelled monoclonal antibody with storage is related to radiation damage. J Nucl Med 26:113

  17. Sakahara H, Endo K, Nakashima T, Koizumi M, Ohta H, Torizuka K, Furukawa T, Ohmono Y, Yokoyama A, Okada K, Yoshida O, Nishi S (1985) Effect of DTPA conjugation on the antigen binding activity and biodistribution of monoclonal antibodies against α-fetoprotein. J Nucl Med 26:750–753

  18. Storch M-J, Lohmann-Matthes M-L (1984) A new and rapid method for immunoglobulin class and subclass determination of mouse monoclonal antibodies using a solid-phase immunoradiometal assay. J Immunol Methods 68:305–309

Download references

Author information

Correspondence to Malcolm V. Pimm.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pimm, M.V., Baldwin, R.W. Comparative tumour localization properties of radiolabelled monoclonal antibody preparations of defined immunoreactivities. Eur J Nucl Med 13, 348–352 (1987). https://doi.org/10.1007/BF00252993

Download citation

Key words

  • Monoclonal antibody
  • Immunoreactive fraction
  • Tumour localization